Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
Expert Opin Emerg Drugs. 2018 Sep 25;:
Authors: Spagnuolo A, Maione P, Gridelli C
PMID: 30251885 [PubMed - as supplied by publisher]
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer